-
XPENG Launches Two New Models in UK; Pony.ai Robotaxi Enters Pilot
-
Broad Clinical Labs Drives Strong Digital Engagement by Connecting Customers with Published Research Through Bioz
-
How to Turn Your Garage into Usable Living Space
-
Pilot-Founded Solara Global Jet Offers Charter, Leases and Air Cargo Nationwide and Overseas
-
Driving Global Innovation - GTDC Summit APJ Underscores Distribution's Transformative Power
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 17
-
PRAAMS AI Co-Investor Now Covers 400,000+ Global Instruments, With Responses From 3 Seconds, Cost From US$0.01, and Scalability to Millions of Users
-
Three Inaugural CombatX Champions Crowned at BRAVE CF Road to BRAVE Event in Hungary
-
French Economy Shrinks 0.1% as Consumer Confidence Slumps
-
China's Factory Activity Contracts as Export Orders Weaken
-
Wall Street Ends Turbulent Week Higher Despite Inflation and AI Jitters
-
US Retail Sales and Fed Minutes Set Up a Critical Test for Consumers
-
Kansas City Fed Chief Says Inflation Is Still Running Too Hot
-
Oil Heads for Second Weekly Loss as Supply Surplus Emerges
-
Luxury Skincare Brand Faces Backlash Over Futurist Manifesto Aesthetic
-
Asian Markets Slide as AI Concerns Hit Chip Stocks
-
Brazil Faces Debt and Inflation Test as Lula Prepares Fourth Term
-
Canada Signals Openness to Chinese Automakers if US Trade Talks Fail
-
Canada Expands Asian Trade Push as US Negotiations Resume
-
US Mortgage Rate Falls for Fourth Week but Remains Above 7%
-
US Jobless Claims Rise to 200,000 but Layoffs Remain Historically Low
-
Italy Raises 2026 Growth View but Warns Energy Will Keep Inflation High
-
Godzilla Minus Zero Review: Takashi Yamazaki’s Anti-Nuclear Allegory
-
Euro-Area Growth Slows to 0.4% While Employment Stalls
-
DA Demands No-Work-No-Pay for Striking Municipal Workers in Coalition Talks
-
UK Economy Grows 0.7% in Third Quarter as Services Lead Expansion
-
US Wholesale Inflation Eases Monthly but Hits a Four-Year Annual High
-
India's Retail Inflation Reaches 6.09% as Food Prices Accelerate
-
India's Wholesale Inflation Jumps to 12.29% as Fuel Costs Surge
-
Malta Emerges as Premier Low-Season Destination for UK Travelers
-
China's October Activity Data Reveal a Weak Start to the Fourth Quarter
-
Japan's Economy Edges Into Contraction as Costly Oil Weighs on Demand
Is DEA Marijuana Lies Civil Misconduct or Criminal Fraud? DEA Administrator's First Marijuana Decision
DEA Counsel's Conduct: Is It Fraud on the Tribunal?
DEA attorney Aarathi D. Haig submitted a formal legal response on July 25, 2025 to DEA Administrator Terry Cole, asserting that MMJ BioPharma Cultivation lacked a bona fide supply agreement (BFSA) - the critical requirement for Schedule I bulk manufacturing registration.
But this is provably false. That misrepresentation - made knowingly and in writing to the DEA Administrator and under the guise of the law - raises serious civil and criminal red flags.
WASHINGTON, DC / ACCESS Newswire / July 29, 2025 / The Drug Enforcement Administration just perjured itself in the matter of MMJ BioPharma Cultivation. In a July 25 filing signed by attorney Aarathi D. Haig, the DEA outrageously claimed that MMJ "had no bona fide supply agreement (BFSA)" with a Schedule I registrant. That statement is not only false; it's demonstrably, documentably false.

We have the signed, sealed BFSA between MMJ BioPharma and a DEA-registered Schedule I manufacturer. The agreement meticulously satisfies every clause of DEA's own regulatory requirement under 21 C.F.R. § 1318.05(b)(3)(i).
This wasn't a technicality. It was a coordinated lie meant to bury seven years of federally compliant work, destroy a Huntington's Disease treatment before it reaches patients, and protect DEA insiders who have weaponized bureaucracy against medical marijuana science.
The Receipts DEA Pretends Don't Exist
Let's be crystal clear: MMJ's supply agreement with a schedule 1 registrant contains every single requirement DEA demanded in its own rules:
Schedule I registrant?
Specific strains and cannabis delivery quantities? Detailed in Article I.
Harvest notifications, packaging, DEA Form 222, and ownership transfer protocols? Articles II & III.
Secure vault storage, anti-diversion controls, payment terms, IRB-reviewed clinical trial data, IND approval from FDA?
Yet the DEA continues to write in federal filings, as though we're all too stupid to read the documents, that MMJ "failed" to provide a Bona Fide Supply Agreement.
This is not a misunderstanding. This is deception and fraudulent misrepresentation at the highest level.
Mulrooney's Kangaroo Court and Aarathi Haig's Legal Fiction
Chief Administrative Law Judge John J. Mulrooney II, now conveniently retired, rubber-stamped this lie and refused to even admit the supply agreement into evidence. He helped orchestrate a procedural sham that made it impossible for MMJ to present the truth.
And now DEA Counsel Aarathi Haig doubles down with a legal sleight of hand that should be called what it is: fraud on the tribunal.
Who Will Hold DEA Accountable?
This isn't just about MMJ BioPharma anymore.
It's about whether facts still matter in federal law.
It's about whether a rogue federal agency can retroactively invent rules, then pretend applicants didn't comply, and get away with it while patients with deadly diseases like Huntington's continue to suffer.
This case exposes DEA's Diversion Control Division as a cartel of obstructionists who have abandoned science, betrayed public trust, and refused to follow the law.
DEA Terrance Cole's First Test as Administrator
New DEA Administrator Terrance Cole inherited a mess. But now he has a chance to do something Mulrooney and Haig never would: Tell the truth. Follow the law. And approve MMJ's long-blocked registration so clinical trials can finally begin.
If Cole doesn't act, he won't just be complicit; he'll become the latest face of a federal agency that has turned cannabis research into a rigged game; a game where the rules change, the facts don't matter, and the fix is always in.
This Is What Scientific Sabotage Looks Like
At stake here is not just one registration; it's the future of FDA compliant, patient focused cannabis research in the United States.
MMJ BioPharma Cultivation has done everything by the book. The DEA burned the book-and then accused MMJ of not reading it.
MMJ is represented by attorney Megan Sheehan.
CONTACT:
Madison Hisey
[email protected]
203-231-8583
SOURCE: MMJ International Holdings
View the original press release on ACCESS Newswire
M.O.Allen--AT